Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 9/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | PDE2A | O00408 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
| ▸ | NOS2 | P35228 | 2/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.35 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23791164 | 0.90 | AR (0.40) | ARSLC22A12HRH4PDE2AALDH1A1 | |
| SCHEMBL16954184 | 0.88 | AR (0.37) | ARKCNJ1KCNH2SLC22A12HRH4 | |
| SCHEMBL16868772 | 0.83 | RORC (0.46) | — | |
| SCHEMBL18119750 | 0.80 | AR (0.40) | ARCYP2D6SLC6A2SLC6A4NOS2 | |
| SCHEMBL22184963 | 0.80 | AR (0.46) | ARPDE2AALDH1A1ACACB | |
| SCHEMBL14549026 | 0.80 | AR (0.58) | ARALDH1A1 | |
| SCHEMBL13523271 | 0.79 | PDE2A (0.45) | PDE2AALDH1A1 | |
| SCHEMBL16959026 | 0.78 | PDE2A (0.38) | ARSLC22A12HRH4PDE2ACYP2D6 | |
| SCHEMBL7133698 | 0.78 | PDE2A (0.40) | ARSLC22A12HRH4PDE2AALDH1A1 | |
| SCHEMBL25027661 | 0.78 | CYP11B1 (0.42) | ARACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230137110-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20230137110-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20220140252-A1 | NOVEL ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2022-05-05 | — | — | US | disclosed |
| US-20220020935-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20210296594-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2021-09-23 | — | — | US | disclosed |
| US-20210280795-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | Beijing Summer Sprout Technology Co., Ltd. (CN) | 2021-09-09 | — | — | US | disclosed |
| US-20100256180-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100256180-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMAPANY (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210296594-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | SLCO2B1, SLCO2A1, SLCO4C1 | AR 3114/4885KCNJ1 161/4885KCNH2 290/4885 |
| US-20210280795-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | SLC18A2, SLC43A1, SLC18A1 | AR 1781/4885KCNJ1 416/4885KCNH2 53/4885 |
| US-20230137110-A1 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF | SLCO2B1, SLCO2A1, SLCO1B3 | AR 3511/4885KCNJ1 35/4885KCNH2 33/4885 |
| US-20220140252-A1 | NOVEL ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | LEF1, PIEZO1, L1CAM | AR 3344/4885KCNJ1 358/4885KCNH2 41/4885 |
| US-20100256180-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | NR5A1, AR, ESRRA | AR 2/4885KCNJ1 4540/4885KCNH2 4537/4885 |
| US-20220020935-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, LEF1 | AR 4173/4885KCNJ1 240/4885KCNH2 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.